Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on CRISPR Therapeutics (CRSP) and raises the price target from $88 to $90.
February 21, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reaffirms a Buy rating on CRISPR Therapeutics and increases the price target to $90.
The upgrade in price target by a reputable analyst like Gil Blum signals a positive outlook on CRISPR Therapeutics, likely leading to increased investor confidence and potentially a short-term rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100